Remarkable response to pembrolizumab with platinum‐doublet in PD‐L1‐low pulmonary sarcomatoid carcinoma: A case report

Pulmonary sarcomatoid carcinoma (SC) is an aggressive subtype of lung cancer that exhibits resistance to cytotoxic chemotherapy. Although programmed cell death 1 (PD‐1) inhibitors have been reported to show antitumor effects in patients with high programmed death‐ligand 1 (PD‐L1) expressing SC, the...

Descripción completa

Detalles Bibliográficos
Autores principales: Taniguchi, Hirokazu, Takemoto, Shinnosuke, Ozasa, Mutsumi, Honda, Noritaka, Suyama, Takayuki, Umeyama, Yasuhiro, Dotsu, Yosuke, Nakao, Takumi, Tomohito, Kojima, Gyotoku, Hiroshi, Yamaguchi, Hiroyuki, Miyazaki, Taiga, Sakamoto, Noriho, Obase, Yasushi, Fukuda, Minoru, Fukuoka, Junya, Mukae, Hiroshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2021
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8017259/
https://www.ncbi.nlm.nih.gov/pubmed/33605089
http://dx.doi.org/10.1111/1759-7714.13890

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8017259/
https://www.ncbi.nlm.nih.gov/pubmed/33605089
http://dx.doi.org/10.1111/1759-7714.13890

Ejemplares similares